U.S. FDA approves Pfizer's Mylotarg for treatment of acute myeloid leukemia
Sept 1 (Reuters) - U.S. Food and Drug Administration::U.S. FDA approves Pfizer's Mylotarg for treatment of acute myeloid leukemia.Prescribing information for Mylotarg includes a boxed warning that severe or fatal liver damage occurred in some patients who took mylotarg.Also approved Mylotarg for patients aged 2 years, older with CD33-positive AML experiencing relapse/ who have not responded to initial treatment.
Latest Developments forPfizer Inc
Latest Key Developments inPharmaceuticals
- Consun Pharmaceutical considering spin-off and listing of Guangxi Yulin Pharmaceutical Group
- VistaGen Therapeutics files for offering of up to $23 mln of common stock
- Abbott CFO says Alere is expected to contribute around $475 mln to reported sales this year
- Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea